Oncology · Neurology ·
US Registry Report Tracks 515,112 Primary Brain and CNS Tumors, 2019–2023
A population-based report using US cancer-registry data identified 515,112 primary brain and other CNS tumors diagnosed from 2019 through 2023. Incidence and survival varied by tumor type, age, sex, and race or Hispanic ethnicity.
- 515,112 tumors were reported for 2019–2023.
- Meningiomas represented 43.4% of diagnoses.
- Incidence and survival varied by demographic and tumor characteristics.
The CBTRUS report describes primary brain and other central nervous system (CNS) tumors diagnosed in the United States from 2019 through 2023. It drew incidence data from 48 registries in the CDC’s National Program of Cancer Registries and four registries in the National Cancer Institute’s SEER Program, covering all 50 states, the District of Columbia, and Puerto Rico. Survival data came from 21 SEER registries.
The report recorded 515,112 tumors, with an average annual age-adjusted incidence rate of 27.02 per 100,000. Meningiomas accounted for 43.4% of diagnoses. Overall incidence was higher in females, while males had higher incidence of several glioma subtypes, including glioblastoma, IDH-wildtype. Among children aged 0–14, these tumors were the leading cause of cancer-related mortality, despite lower incidence in this age group. Five-year relative survival generally declined with increasing age. These descriptive registry findings document variation across population groups and tumor types; they do not evaluate causes or treatment effects.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Neuro-Oncology: CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2019−2023 ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.